The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
PD-1 Blockade Expands Intratumoral Memory T Cells
Open accessPublished version of a preprint
Abstract
Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated by T cells, which we characterized in 102 tumor biopsies obtained from 53 patients treated with pembrolizumab, an antibody to PD-1. Biopsies were dissociated, and single-cell infiltrates were analyzed by multicolor flow cytometry using two computational approaches to resolve the leukocyte phenotypes at the single-cell level. There was a statistically significant increase in the frequency of T cells in patients who responded to therapy. The frequency of intratumoral B cells and monocytic myeloid-derived suppressor cells significantly increased in patients' biopsies taken on treatment. The percentage of cells with a regulatory T-cell phenotype, monocytes, and natural killer cells did not change while on PD-1 blockade therapy. CD8+ memory T cells were the most prominent phenotype that expanded intratumorally on therapy. However, the frequency of CD4+ effector memory T cells significantly decreased on treatment, whereas CD4+ effector T cells significantly increased in nonresponding tumors on therapy. In peripheral blood, an unusual population of blood cells expressing CD56 was detected in two patients with regressing melanoma. In conclusion, PD-1 blockade increases the frequency of T cells, B cells, and myeloid-derived suppressor cells in tumors, with the CD8+ effector memory T-cell subset being the major T-cell phenotype expanded in patients with a response to therapy. Cancer Immunol Res; 4(3); 194–203. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Examination of the lymphocytes that correlated with such beneficial outcomes has repeatedly implicated effector and memory CD8 + T cell and NK cell populations (136-141).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Clinical responses to PD-1 blockade are associated with increased PD-L1 expression on tumor-resident cells, induced by preexisting tumor-infiltrating lymphocytes (TIL), in what is termed "adaptive immune resistance" (1, 10, 13).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“In fact, IHC and transcriptome analyses of on-therapy tumor biopsies suggest that several inflammatory cells and markers increase with anti–PD-1 or anti–PD-L1 treatment (10, 13).”
BackgroundSelf-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“In fact, IHC and transcriptome analyses of on-therapy tumor biopsies suggest that several inflammatory cells and markers increase with anti–PD-1 or anti–PD-L1 treatment (10, 13).”
BackgroundThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 4×
“In fact, IHC and transcriptome analyses of on-therapy tumor biopsies suggest that several inflammatory cells and markers increase with anti–PD-1 or anti–PD-L1 treatment (10, 13).”
ResultInfluentialPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256 · cited 1×
“PD-1 limits the activity of T cells by inducing a phosphatase that inhibits T-cell receptor downstream signaling (2, 4, 5).”
Background
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
“Expansion of intratumoural T(EM) in response to PD-1 blockade has been demonstrated, and is more pronounced in patients responding to therapy (Ribas et al, 2016b), suggesting a key role for TEM cells in anti-PD-1 action and clinical response (O’Donnell et al, 2017).”
BackgroundInfluentialMolecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159
Self-citation
Metadata
- Authors
- Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., Wang, X., Chmielowski, B., Glaspy, J. A., Tumeh, P. C., Chodon, T., Pe'er, D., & Comin-Anduix, B.
- Affiliations
- University of California, Los Angeles (US)
- Technical University of Denmark (DK)
- Columbia University (US)
- 7CytoAnalysis, Denver, Colorado.
- 1Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
- Roswell Park Comprehensive Cancer Center (US)
- 6Departments of Biological Sciences and Systems Biology, Columbia University, New York, New York.
- 2Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California.
- Corresponding author
- Ribas, Antoni
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2016-02-29
- Volume
- 4
- Issue
- 3
- Pages
- 194-203
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC4775381
- OpenAlex
- W2281666530
- Cited by
- 405
- References
- 51
- Citations by year
- 2026: 23 · 2025: 21 · 2024: 36 · 2023: 40 · 2022: 38 · 2021: 44 · 2020: 58 · 2019: 61 · 2018: 35 · 2017: 36 · 2016: 13
- FWCI
- 26.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, other-oa)
- Funders
- NIH, Cancer Research Institute and Cancer Immunology Dream Team Translational Research (R35 CA197633, P01 CA168585, SU2C-CRI, SU2C-AACR-DT1012)
- Cancer Phillip A. Sharp Innovation (SU2C-AACR-PS04)
- Tower Cancer Research Foundation (5T32CA009297-30, 5T32AR058921-05, 5T32CA009120-39)
- NIH and JCCC, JCCC, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA (CA16042, AI 28697)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- anti-PD-1 therapy, pembrolizumab, intratumoral T cells, memory CD8+ T cells, CD4+ effector memory T cells, myeloid-derived suppressor cells, tumor-infiltrating B cells, melanoma regression, antitumor immunity, cancer immunotherapy
- MeSH terms
- Aged, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, T-Lymphocyte Subsets, Treatment Outcome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PD-1 Blockade Expands Intratumoral Memory T Cells. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0210
- The paper
- Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., Wang, X., Chmielowski, B., Glaspy, J. A., Tumeh, P. C., Chodon, T., Pe'er, D., & Comin-Anduix, B. (2016). PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.